This company has been marked as potentially delisted and may not be actively trading. Jupiter Neurosciences (JUNS) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsFDA EventsHeadlinesInsider TradesShort InterestTrendsBuy This Stock JUNS vs. CBIO, OABI, HRTX, IRWD, TNXP, ACRS, MDWD, SXTC, DERM, and AVTXShould you be buying Jupiter Neurosciences stock or one of its competitors? The main competitors of Jupiter Neurosciences include Crescent Biopharma (CBIO), OmniAb (OABI), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD), Tonix Pharmaceuticals (TNXP), Aclaris Therapeutics (ACRS), MediWound (MDWD), China SXT Pharmaceuticals (SXTC), Journey Medical (DERM), and Avalo Therapeutics (AVTX). These companies are all part of the "med - drugs" industry. Jupiter Neurosciences vs. Its Competitors Crescent Biopharma OmniAb Heron Therapeutics Ironwood Pharmaceuticals Tonix Pharmaceuticals Aclaris Therapeutics MediWound China SXT Pharmaceuticals Journey Medical Avalo Therapeutics Crescent Biopharma (NASDAQ:CBIO) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings. Which has stronger valuation and earnings, CBIO or JUNS? Jupiter Neurosciences has higher revenue and earnings than Crescent Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCrescent Biopharma$10K23,381.80-$37.88M-$34.93-0.34Jupiter Neurosciences$230K234.72-$2.44MN/AN/A Does the media prefer CBIO or JUNS? In the previous week, Crescent Biopharma had 2 more articles in the media than Jupiter Neurosciences. MarketBeat recorded 2 mentions for Crescent Biopharma and 0 mentions for Jupiter Neurosciences. Jupiter Neurosciences' average media sentiment score of 0.94 beat Crescent Biopharma's score of 0.66 indicating that Jupiter Neurosciences is being referred to more favorably in the news media. Company Overall Sentiment Crescent Biopharma Positive Jupiter Neurosciences Positive Do insiders & institutionals believe in CBIO or JUNS? 75.2% of Crescent Biopharma shares are held by institutional investors. 8.7% of Crescent Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is CBIO or JUNS more profitable? Crescent Biopharma's return on equity of -106.06% beat Jupiter Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Crescent BiopharmaN/A -106.06% -86.60% Jupiter Neurosciences N/A -835.24%-155.10% Do analysts recommend CBIO or JUNS? Crescent Biopharma currently has a consensus price target of $25.60, indicating a potential upside of 114.05%. Given Crescent Biopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Crescent Biopharma is more favorable than Jupiter Neurosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Crescent Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 SummaryCrescent Biopharma beats Jupiter Neurosciences on 11 of the 14 factors compared between the two stocks. Get Jupiter Neurosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for JUNS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JUNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JUNS vs. The Competition Export to ExcelMetricJupiter NeurosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.99M$2.65B$6.12B$10.63BDividend YieldN/A56.92%5.70%4.74%P/E Ratio-8.1623.6885.6827.43Price / Sales234.72785.30623.15138.97Price / CashN/A169.9037.7861.77Price / Book11.925.5013.146.74Net Income-$2.44M$32.78M$3.30B$276.22M Jupiter Neurosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JUNSJupiter NeurosciencesN/A$1.55+0.6%N/AN/A$53.99M$230K-8.165Analyst UpgradeCBIOCrescent Biopharma4.3858 of 5 stars$12.15-1.1%$25.60+110.7%N/A$237.53M$10K-0.3550OABIOmniAb2.0814 of 5 stars$1.62+0.3%$6.67+312.8%-57.8%$232.49M$23.03M-2.697HRTXHeron Therapeutics3.5673 of 5 stars$1.26-1.2%$4.50+258.6%-32.7%$230.06M$149.69M-62.75300Analyst ForecastIRWDIronwood Pharmaceuticals4.4558 of 5 stars$1.41-1.1%$4.94+251.6%-62.1%$228.21M$351.41M-28.09220Positive NewsAnalyst UpgradeTNXPTonix Pharmaceuticals2.8643 of 5 stars$24.44-1.3%$70.00+186.4%+59.8%$213.66M$9.83M-0.6250Analyst ForecastACRSAclaris Therapeutics2.6132 of 5 stars$1.85-3.9%$8.71+372.3%+60.0%$199.87M$18.72M-1.35100Positive NewsMDWDMediWound1.6407 of 5 stars$17.99+0.1%$32.25+79.3%+7.5%$194.11M$19.86M-6.8080Analyst ForecastSXTCChina SXT Pharmaceuticals0.4195 of 5 stars$1.65+1.5%N/A-71.8%$190.87M$1.74M0.0090Analyst ForecastDERMJourney Medical1.4848 of 5 stars$7.04-0.8%$12.17+72.8%+20.0%$185.25M$56.13M-18.5390News CoveragePositive NewsAnalyst ForecastAVTXAvalo Therapeutics3.142 of 5 stars$12.91-0.8%$31.67+145.3%+39.9%$169.79M$441K0.0040 Related Companies and Tools Related Companies CBIO Competitors OABI Competitors HRTX Competitors IRWD Competitors TNXP Competitors ACRS Competitors MDWD Competitors SXTC Competitors DERM Competitors AVTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JUNS) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredU.S. Government Sparking Crypto RallyAltcoin ETFs could surge prices (do this now) My "Crypto Bull Run Millionaire Blueprint" breaks down exactl...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jupiter Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jupiter Neurosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
